Connecting you to content on EBSCOhost

Works by Seung-Ah Cho

Results: 3

1

Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial.

Published in:

Diabetes & Metabolism Journal, 2023, v. 47, n. 6, p. 796, doi. 10.4093/dmj.2022.0315

By:

Kyung Ah Han;
Yong Hyun Kim;
Doo Man Kim;
Byung Wan Lee;
Suk Chon;
Tae Seo Sohn;
In Kyung Jeong;
Eun-Gyoung Hong;
Jang Won Son;
Jae Jin Nah;
Hwa Rang Song;
Seong In Cho;
Seung-Ah Cho;
Kun Ho Yoon

Publication type:

Article

2

Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 10, p. 4203, doi. 10.1111/dom.15738

By:

Kwak, Soo Heon;
Han, Kyung Ah;
Kim, Eun Sook;
Choi, Sung Hee;
Won, Jong Chul;
Yu, Jae Myung;
Oh, Seungjoon;
Yoo, Hye Jin;
Kim, Chong Hwa;
Kim, Kyung‐Soo;
Chun, SungWan;
Kim, Yong Hyun;
Cho, Seung Ah;
Kim, Da Hye;
Park, Kyong Soo

Publication type:

Article

3

Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1865, doi. 10.1111/dom.15046

By:

Kwak, Soo Heon;
Han, Kyung Ah;
Kim, Kyung‐Soo;
Yu, Jae Myung;
Kim, EunSook;
Won, Jong Chul;
Kang, Jun Goo;
Chung, Choon Hee;
Oh, Seungjoon;
Choi, Sung Hee;
Won, Kyu Chang;
Kim, Sin Gon;
Cho, Seung Ah;
Cho, Bo Young;
Park, Kyong Soo

Publication type:

Article